The Annals of Neurology study (Yuan Ding et al., 2026) employed Mendelian Randomization—an observational genetic method stronger than standard epidemiology but not an RCT—to screen >2,500 plasma proteins in UK Biobank data. Among 500,000 participants, only 124 incident MS cases were identified with pre-diagnostic samples (mean 6 years prior), revealing 8 altered proteins including DKKL1. This small case count limits statistical power and generalizability, with no reported conflicts disclosed in the primary paper. While MedicalXpress framed the work as an MS-specific prevention window akin to cholesterol screening, it overlooked the broader pre-symptomatic biomarker convergence now documented across autoimmune and neurodegenerative diseases. Integration with a 2020 Nature Medicine proteomic analysis of Alzheimer’s (n>1,000, longitudinal plasma markers preceding cognitive decline by 5–10 years) and a 2023 Lancet Neurology study on rheumatoid arthritis autoantibodies (pre-clinical detection in 40% of future cases) shows immune-signaling proteins like those in the MS network frequently dysregulated years earlier. These patterns suggest shared upstream pathways rather than disease-isolated signals, enabling potential multi-disease risk panels. Mainstream reporting rarely links them because specialty silos persist, delaying translation to combined screening. Larger validation cohorts remain essential before clinical use.